(Q37693873)

English

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine

scientific article published on 13 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

1 reference

based on heuristic

inferred from title

tumour xenograft

1 reference

based on heuristic

inferred from title

author name string

Kandasamy Hariharan

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Peter Chu

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Tracey Murphy

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dana Clanton

4

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Lisa Berquist

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Arturo Molina

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Steffan N Ho

7

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Mario I Vega

8

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Benjamin Bonavida

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

publication date

13 June 2013

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

International Journal of Oncology

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

43

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

670-676

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

23 August 2017

A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

23 August 2017

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

23 August 2017

The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

23 August 2017

CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

23 August 2017

Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

6 September 2017

New therapeutic targets and drugs in non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

6 September 2017

Transformation of indolent B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

6 September 2017

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

14 September 2017

Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

28 September 2017

Treatment of non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

28 September 2017

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

1 September 2018

The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

2 October 2018

Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

2 October 2018

In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3981005

5 November 2018

In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23764770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23764770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23764770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23764770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23764770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23764770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3892/IJO.2013.1986

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37693873&oldid=2094872580"